INM
InMed Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.38
+3.76%Margins
Gross margin
30.4%
EBITDA margin
-229.5%
EBIT margin
-246.8%
Net margin
-246.4%
FCF margin
-223.9%
-143.8%
Return on equity
-108.5%
Return on assets
-135.8%
Return on invested capital
0.33x
Asset turnover
-$9.0M
Cash from operations
$0.97
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026